JPMorgan Chase & Co. Reaffirms “Buy” Rating for Moderna (NASDAQ:MRNA)

JPMorgan Chase & Co. reissued their buy rating on shares of Moderna (NASDAQ:MRNA) in a research report report published on Sunday, reports. The firm currently has a $24.00 target price on the stock.

MRNA has been the subject of several other research reports. Chardan Capital reaffirmed a buy rating and issued a $40.00 price target on shares of Moderna in a report on Sunday, June 2nd. Oppenheimer upped their price target on Moderna from $27.00 to $31.00 and gave the company an outperform rating in a report on Wednesday, May 29th. Piper Jaffray Companies upped their price target on Moderna from $24.00 to $30.00 and gave the company an overweight rating in a report on Wednesday, May 8th. Finally, Zacks Investment Research raised Moderna from a hold rating to a buy rating and set a $15.00 price target for the company in a report on Saturday. Ten analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and an average target price of $26.30.

Moderna stock opened at $13.30 on Friday. The firm has a 50 day moving average price of $13.90. The firm has a market cap of $4.39 billion and a PE ratio of -2.69. Moderna has a 12 month low of $11.54 and a 12 month high of $29.79.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

See Also: Compound Interest

Analyst Recommendations for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with's FREE daily email newsletter.